Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2Plasma cell 1Myeloid 1Classical hematology 1

Conditions

Recurrence 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 88fludarabine phosphate 77Busulfan 56Tacrolimus 54Mycophenolic Acid 54Antilymphocyte Serum 48Peripheral Blood Stem Cell Transplantation 46Filgrastim 42Melphalan 41Cyclosporine 39Whole-Body Irradiation 38fludarabine 36Radiotherapy 32Methotrexate 28Cord Blood Stem Cell Transplantation 25Methylprednisolone 24Alemtuzumab 17Etoposide 16Thiotepa 15Rituximab 14Cytarabine 14thymoglobulin 13Granulocyte Colony-Stimulating Factor 12Stem Cell Transplantation 10sargramostim 9Sirolimus 9Flow Cytometry 9Psychiatric Rehabilitation 8Prednisone 7Mesna 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × darinaparsin × Myeloid × Clear all
NCT00592046 2012-07-19

A Phase I Trial of ZIO-101 in Hematologic Cancers

Alaunos Therapeutics

Phase 1 Completed
12 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡